BioCardia (NASDAQ:BCDA – Get Free Report) and Humacyte (NASDAQ:HUMA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Insider and Institutional Ownership
20.6% of BioCardia shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 20.0% of BioCardia shares are held by company insiders. Comparatively, 5.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares BioCardia and Humacyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | -1,999.77% | N/A | -208.38% |
| Humacyte | N/A | -942.81% | -93.82% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 0 | 0 | 1 | 1 | 3.50 |
| Humacyte | 0 | 1 | 6 | 1 | 3.00 |
BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 1,046.79%. Humacyte has a consensus price target of $11.71, indicating a potential upside of 394.27%. Given BioCardia’s stronger consensus rating and higher possible upside, equities analysts plainly believe BioCardia is more favorable than Humacyte.
Risk and Volatility
BioCardia has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500.
Valuation and Earnings
This table compares BioCardia and Humacyte”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $3,000.00 | 3,762.68 | -$11.57 million | ($2.33) | -0.94 |
| Humacyte | $517,000.00 | 711.09 | -$110.78 million | ($0.69) | -3.43 |
BioCardia has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
